Arvest Trust Co. N A increased its position in Pfizer Inc. (NYSE:PFE – Get Rating) by 7.3% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 364,750 shares of the biopharmaceutical company's stock after purchasing an additional 24,855 shares during the period. Pfizer accounts for about 1.1% of Arvest Trust Co. N A's investment portfolio, making the stock its 29th biggest holding. Arvest Trust Co. N A's holdings in Pfizer were worth $15,961,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. RB Capital Management LLC lifted its holdings in Pfizer by 6.7% in the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company's stock worth $282,000 after acquiring an additional 341 shares during the last quarter. Ironwood Wealth Management LLC. lifted its holdings in Pfizer by 1.1% in the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company's stock worth $1,868,000 after acquiring an additional 400 shares during the last quarter. United Bank lifted its holdings in Pfizer by 0.6% in the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company's stock worth $2,416,000 after acquiring an additional 290 shares during the last quarter. Ergoteles LLC lifted its holdings in Pfizer by 136.3% in the first quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company's stock worth $1,903,000 after acquiring an additional 21,209 shares during the last quarter. Finally, Mackenzie Financial Corp lifted its holdings in Pfizer by 6.4% in the first quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company's stock worth $69,238,000 after acquiring an additional 79,887 shares during the last quarter. 67.62% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Down 0.5 %

PFE opened at $44.02 on Friday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.37 and a current ratio of 1.59. The company has a market capitalization of $247.10 billion, a PE ratio of 8.51, a P/E/G ratio of 1.11 and a beta of 0.67. The stock's fifty day moving average is $49.62 and its 200-day moving average is $48.04. Pfizer Inc. has a one year low of $41.44 and a one year high of $56.32.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 3rd. Shareholders of record on Friday, January 27th will be given a $0.41 dividend. The ex-dividend date is Thursday, January 26th. This is a boost from Pfizer's previous quarterly dividend of $0.40. This represents a $1.64 annualized dividend and a yield of 3.73%. Pfizer's payout ratio is 30.77%.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. The Goldman Sachs Group raised shares of Pfizer from a "neutral" rating to a "buy" rating and raised their target price for the stock from $47.00 to $60.00 in a report on Tuesday, December 13th. StockNews.com assumed coverage on shares of Pfizer in a research note on Wednesday, October 12th. They issued a "strong-buy" rating on the stock. Morgan Stanley raised their price target on shares of Pfizer from $51.00 to $53.00 and gave the company an "equal weight" rating in a research note on Wednesday, December 14th. JPMorgan Chase & Co. set a $50.00 price target on shares of Pfizer in a research note on Wednesday, January 18th. Finally, Credit Suisse Group set a $54.00 price target on shares of Pfizer in a research note on Wednesday, January 18th. Eight research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of "Hold" and a consensus target price of $52.33.

About Pfizer

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

See Also

• Get a free copy of the StockNews.com research report on Pfizer (PFE)
• ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
• KLA Corporation: Strength In A Troubled Semi-Market
• PCE Indicates Slowdown In Spending, Economy Weakens
• Microsoft's Comeback Is Now Underway
• Can Amazon Recover Amid Tech Stock Sell-off?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.